IPO - Profile

Summary

We are a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Our initial focus is on advancing AV-101, our dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, or PAH, a devastating disease impacting approximately 70,000 people in the United States and Europe. Imatinib, marketed as Gleevec tablets, was originally developed for the treatment of multiple cancers.

Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$14.00 8,700,000 Positive High 13%

Offering Team

  • Legal counsel
  • Goodwin Procter LLP
  • Auditors
  • KPMG LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 29 Jun, 2021

Offer 30 Jun, 2021

Look Ahead

Lock Up Expiry Dec 30, 2021

IPO Terms

Offer Price $14.00
Offer Size 8M

Market Sentiments

Stock Price